Pharmacogenetic testing to improve care in the emergency department
5 affiliations
- 1Department of Pharmacy, University of Florida Health
- 2Center for Pharmacogenomics and Precision Medicine, University of Florida College of Pharmacy
- 3Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy
- 4Department of Pharmacy Practice and Science, The Ohio State University College of Pharmacy
- 5Department of Emergency Medicine, University of Florida College of Medicine-Jacksonville
Abstract
Nearly 20% of emergency department (ED) encounters involve medications with actionable pharmacogenomic (PGx) guidance available, and population-based studies suggest over 90% of patients carry at least one PGx variant potentially affecting drug response. Despite this, PGx testing in emergency medicine remains rare. This perspective summarizes current evidence supporting PGx implementation in the ED, key barriers to integration, and future directions for PGx testing in acute care. Feasibility studies demonstrate that PGx testing can be incorporated into ED workflows. Observational data suggest clinically important associations between CYP2C19 variability and clopidogrel-related bleeding, CYP2D6 metabolism and opioid-related ED visits, and a high prevalence of actionable gene–drug interactions in older adults presenting with falls. In pediatric psychiatric populations, combinatorial PGx testing has been associated with differences in drug exposure and clinical outcomes. However, no randomized controlled trials testing the clinical utility of PGx testing have been conducted in ED populations. Key barriers to implementation include prolonged PGx testing turnaround times, lack of standardized ordering workflows, limited clinician familiarity with PGx interpretation, inconsistent reimbursement, and challenges integrating results into clinical decision support systems. Future priorities should include prospective interventional trials assessing clinical outcomes, targeted implementation focused on high-risk gene-drug pairs, and incorporation of PGx education into emergency medicine training. Although current evidence is largely feasibility-based, the ED represents a potentially high-yield setting for PGx integration given frequent exposure to actionable medications and the high burden of potentially preventable adverse drug events.
Related
- The effectiveness of point of care high sensitivity troponin testing to improve Emergency Department flow: a multi-centre controlled interrupted time series
- Cost-effectiveness of prehospital high-sensitivity troponin i testing versus standard emergency department care in patients with suspected acute coronary syndrome in France
- Emergency department medical care during civil unrest: thank you for looking at the eyes
- Automated Calculation of the Pediatric Emergency Care Applied Research Network (PECARN) Intra-Abdominal Injury Rule from Unstructured Emergency Department Notes Using a Large Language Model
- A Mixed Methods Evaluation of a Model of Care for Domestic Violence Within the Emergency Department
BibTeX
@article{gartner2026pharmacogenetic,
title = {{Pharmacogenetic testing to improve care in the emergency department}},
author = {Hayley T. Gartner and Julio D. Duarte and Sophia Sheikh},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1866821},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1866821/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pharmacogenetic testing to improve care in the emergency department
AU - Hayley T. Gartner
AU - Julio D. Duarte
AU - Sophia Sheikh
PY - 2026
DA - 2026/10/21
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1866821
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1866821/full
AB - Nearly 20% of emergency department (ED) encounters involve medications with actionable pharmacogenomic (PGx) guidance available, and population-based studies suggest over 90% of patients carry at least one PGx variant potentially affecting drug response. Despite this, PGx testing in emergency medicine remains rare. This perspective summarizes current evidence supporting PGx implementation in the ED, key barriers to integration, and future directions for PGx testing in acute care. Feasibility studies demonstrate that PGx testing can be incorporated into ED workflows. Observational data suggest clinically important associations between CYP2C19 variability and clopidogrel-related bleeding, CYP2D6 metabolism and opioid-related ED visits, and a high prevalence of actionable gene–drug interactions in older adults presenting with falls. In pediatric psychiatric populations, combinatorial PGx testing has been associated with differences in drug exposure and clinical outcomes. However, no randomized controlled trials testing the clinical utility of PGx testing have been conducted in ED populations. Key barriers to implementation include prolonged PGx testing turnaround times, lack of standardized ordering workflows, limited clinician familiarity with PGx interpretation, inconsistent reimbursement, and challenges integrating results into clinical decision support systems. Future priorities should include prospective interventional trials assessing clinical outcomes, targeted implementation focused on high-risk gene-drug pairs, and incorporation of PGx education into emergency medicine training. Although current evidence is largely feasibility-based, the ED represents a potentially high-yield setting for PGx integration given frequent exposure to actionable medications and the high burden of potentially preventable adverse drug events.
SN - 1663-9812
ER -